The subscription period in aXichem’s rights issue begins today
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, EITHER DIRECTLY OR INDIRECTLY, WITHIN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL REGISTRATIONS OR OTHER MEASURES NOT STIPULATED BY SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.
The subscription period in aXichem AB (publ)'s ("aXichem" or the "Company") rights issue of shares, resolved by the Board of Directors on February 23, 2023 (the "Rights Issue"), begins today.
Summary of the Rights Issue
- One (1) existing share gives one (1) subscription right. Seven (7) subscription rights give the right to subscribe for three (3) newly issued shares.
- The subscription price is SEK 7.00 per share. If fully subscribed, the Company will receive SEK 49.6 million before issue costs.
- In connection with the Rights Issue, the Company has received subscription commitments from a number of existing shareholders for a total of approximately SEK 7.7 million, corresponding to approximately 15 percent of the Rights Issue. In addition, aXichem has entered into guarantee commitments for a total of approximately SEK 27.1 million, corresponding to approximately 55 percent of the Rights Issue. The Rights Issue is thus covered by subscription commitments and guarantee commitments of a total of approximately SEK 34.7 million, corresponding to 70 percent of the Rights Issue. The subscription commitments and guarantee commitments are not secured by bank guarantee, restricted funds, pledged assets or similar arrangements. More detailed information about the parties that have entered into subscription commitments and guarantee commitments can be found in the Prospectus, which was published on March 3, 2023.
Timetable for the Rights Issue
8 March – 22 March 2023 Subscription period
8 March – 17 March 2023 Trading in subscription rights
8 March – Until the Rights Issue is registered with
the Swedish Companies Registration Office Trading in paid subscribed shares ("BTA")
24 March 2023 Expected date for publication of results in the Rights Issue
The prospectus, which contains complete terms, conditions and instructions, is available on the Company's, Nordic Issuing AB's and Västra Hamnen Corporate Finance AB's respective websites (www.axichem.com, www.nordic-issuing.se, www.vhcorp.se). The prospectus is also available on the Finansinspektionen's website (www.fi.se).
Presentations for investors
On Tuesday, March 14, 2023 at 4:00 p.m., the Company's CEO, Torsten Helsing, will give a presentation at Aktiespararna's event "Stora Aktiedagarna" in Stockholm. Questions to the Company can be sent to Aktiespararna before the event and registration can be sent via the following link: https://www.aktiespararna.se/aktiviteter/stora-aktiedagen-i-stockholm-14-mars.
In addition, Västra Hamnen Corporate Finance will host an online company presentation with CEO Torsten Helsing on Thursday, March 16, 2023 at 2:00 p.m. After the presentation, the audience is given the opportunity to ask questions. Questions can also be asked in advance to [email protected] The presentation is held in Swedish and can be attended through computer or mobile devices. Registration for the online presentation is sent via the following link: https://attendee.gotowebinar.com/register/8536926466527011677
Financial advisers, legal advisers and issuing agent
Västra Hamnen Corporate Finance AB (publ) acts as financial adviser and Vinge acts as legal adviser to aXichem in connection with the rights issue. Nordic Issuing acts as issuing agent.
For further information:
CEO, aXichem AB, phone: +46 706 863 355
Email: [email protected]
Or visit: www.axichem.com
Certified advisor for aXichem is Västra Hamnen Corporate Finance AB.
The information was submitted, through the agency of the contact person, for publication on March 8, 2023, at 08:30 AM CET.
Torsten Helsing, CEO, aXichem, Ph+46 70 686 33 55. Email: [email protected]
aXichem’s business idea is to develop, patent and market natural analogue industrial compounds. The Company primarily works with phenylcapsaicin a structural analogue of capsaicin with a wide range of applications, such as feed additives, nutraceuticals and certain pharmaceutical areas. aXichem’s shares are listed on NASDAQ First North Growth Market under AXIC A. Certified Adviser: Västra Hamnen Corporate Finance, www.vhcorp.se. Read more about aXichem at www.axichem.se
Studie med gentestet Prostatype® publicerat i ledande internationell tidskrift
Studien som genomförts av ett forskningsteam på Akademiska sjukhuset i Uppsala under ledning av docent och överläkare Michael Häggman visar att gentestet Prostatype® korrekt bedömer prostatacancertumörens aggressivitet när man jämför genuttryck från vävnadsprover, så kallade biopsier, med ”fac...
ViroGates announces its Annual Report 2022: Growing revenue by 33% and more than tripling the customer base in clinical routine
BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, announces its Annual Report for the period 1 January – 31 December 2022, as approved today by the company’s Board of Directors....
AegirBio AB: Atlas Special Opportunities, LLC calls for partial conversion of outstanding convertible bonds to a nominal amount of MSEK 10.00
On 20 December 2022 AegirBio AB (“AegirBio” or the “Company”) announced that the Company had agreed on a convertible financing agreement with Atlas Special Opportunities, LLC (“Atlas”) regarding convertible bonds amounting to MSEK 55.00 (the “Convertible Bonds”) with attached warrants. On 20Ja...
AegirBio AB: Atlas Special Opportunities, LLC påkallar partiell konvertering av utestående konvertibler till ett nominellt belopp om 10,00 MSEK
Den 20 december 2022 meddelade AegirBio AB (”AegirBio” eller ”Bolaget”) att Bolaget avtalat om en konvertibelfinansiering med Atlas Special Opportunities, LLC (”Atlas”) avseende konvertibler om 55,00MSEK (”Konvertiblerna”) med vidhängande teckningsoptioner. Bolagsstämman beslutade den 20...